BlueCross BlueShield
Federal Employee Program

KOSELUGO
(selumetinib)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 2 years of age or older

Diagnosis

Patient must have the following:

Neurofibromatosis Type 1 (NF1)

AND ALL of the following**:**

a. Patient is symptomatic
b. Patient has plexiform neurofibromas (PN) that are inoperable
c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose
d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose
e. Baseline ophthalmic assessment has been done and prescriber agrees to monitor for ocular toxicities
f. Baseline left ventricular ejection fraction (LVEF) has been assessed and prescriber agrees to monitor LVEF

Prior - Approval Limits

Quantity 720 capsules per 90 days
Duration 12 months

Prior – Approval *Renewal* Requirements

Age 2 years of age or older

Diagnosis

Patient must have the following:

Neurofibromatosis Type 1 (NF1)

KOSELUGO
(selumetinib)

AND ALL of the following:

a. **NO** disease progression or unacceptable toxicity
b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose
c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose
d. Prescriber agrees to monitor for ocular toxicities
e. Prescriber agrees to monitor left ventricular ejection fraction (LVEF)

Prior - Approval *Renewal* Limits

Same as above